16 OUTCOMES IN PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROME RECEIVING EX-VIVO T-CELL DEPLETED OR UNMODIFIED ALLOGRAFTS: COMPARISON OF RESULTS AT TWO INSTITUTIONS